|Articles|July 1, 1999

Rep applies Rx training to sales

When asking doctors whether or not they have been prescribing a drug, specialty sales rep David Schwartz's advice is, "Don't accept yes or no for an answer."

When asking doctors whether or not they have been prescribing a drug, specialty sales rep David Schwartz's advice is, "Don't accept yes or no for an answer." Though many reps take a doctor's hurried, positive answer as a sign that their work is done, Schwartz's work has just begun. "It's time to start asking questions," he said. To Schwartz, a rep's job is just as much about listening to doctors as it is about detailing products.

The Pharmacia & Upjohn rep, a seven-time winner of the company's Premiere Award Now (formerly called the Upjohn Academy), practiced pharmacy for one and a half years before turning to sales. "I always thought it would be fun to meet the doctors that called in the prescriptions," he said. "It was the best move I ever made."

This expertise has given Schwartz what he admits is "a huge edge," in sales. Still a registered pharmacist, Schwartz completes 12 hours of continuing education per year and is an active member of the Harris Co. Pharmacy Association. "I always try to teach [new reps] the importance of calling on pharmacists," he said.

Schwartz remembers many Saturdays early in his 26-year career detailing pharmacists on his days off from physicians' calls.

His satisfaction comes from making a difference. "When a doctor sees you in the hall and says, 'You saved my patient's life last night,' that's a real nice feeling," he said. But his favorite part of being a rep? "Talking, and meeting people," he said with a laugh. "I love my job."


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.